GLP-1 Market
LLY $1123.00 ▼ -0.1% NVO $44.01 ▼ -1.2% PFE $27.65 ▼ -0.5% VKTX $32.13 ▼ -1.7% KLRA $14.91 ▲ +0.5% GPCR $39.55 ▼ -4.1% RHHBY $53.19 ▼ -0.4% HIMS $27.44 ▼ -1.6% WW $14.78 ▼ -1.1%
Delayed · As of 9:20 AM

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

Glucagon-like peptide-1 receptor agonist：Semaglutide

Company
The First Affiliated Hospital with Nanjing Medical University
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
1 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

1 recruiting study currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Sep 11, 2026

Find a Clinical Trial Near Me

See recruiting studies for Glucagon-like peptide-1 receptor agonist：Semaglutide and check eligibility with the study team.

Select conditions
Match
Treatment type

"Added to GLP-1" means the investigational treatment is being studied on top of an existing GLP-1-based therapy.

Your ZIP code is only used to calculate distance to trial sites — it isn't stored.

Trial details
  • Recruiting NCT NCT06461377

    The Ameliorative Effects of GLP-1RA on Diabetic Cardiac Autonomatic Neuropathy

    Not yet reported The First Affiliated Hospital with Nanjing Medical University 50 participants Est. completion 2027-12-31 1 site Added to GLP-1
    Type 2 diabetes Other conditions: Diabetes With Diabetic Autonomic Neuropathy (Diagnosis)
    View official trial listing →
  • Not yet recruiting NCT NCT07770152

    Semaglutide in Youth With Autism Spectrum Disorder

    Not yet reported Children's Hospital Medical Center, Cincinnati 42 participants Est. completion 2029-09-01 1 site Stand-alone
    Other conditions: Autism Spectrum Disorder, Obesity
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources
Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.